Curis Inc
Curis Inc logo
CRIS

Curis Inc (CRIS)

$0.79743.26%

Market is closed
– opens on 8 PM, 01 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$0.77
Day's Range
$0.8
$0.68
52-Week Range
$5.27
1 month return3.5%
3 month return23.54%
1 year return84.18%
5 year return80.58%

Company Information

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1 in patients with non-Hodgkin's lymphoma both as a monotherapy and in combination the with BTK inhibitor ibrutinib. Curis is also evaluating CA-4948 in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1a/1b trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma.
OrganizationCuris Inc
Employees60
CEOMr. James E. Dentzer
IndustryHealth Technology

Analyst Recommendation

based on 5 analysts ratings

Buy
100%
Buy
0%
Hold
0%
Sell

Based on 5 Wall street analysts offering stock ratings for Curis Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 1122.72%

Current

$0.8

Target

$9.75

Recommendation Trend

Based on 5 analyst

Current1M Ago3M Ago
Buy
5
9
9
Hold
0
2
2
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
78.1M
Book Value
$0.58
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.56
PEG Ratio
0.0
Wall Street Target Price
9.75

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)
1.45
Enterprise Value
-13735094
Enterprise Value/Revenue
0.01
Enterprise Value/Ebitda
0.25

Technicals

Beta
2.67
50 Day MA
0.79
200 Day MA
1.32

Institutional Holdings

Maverick Capital Ltd

7.98%

M28 Capital Management LP

4.65%

Nantahala Capital Management, LLC

3.76%

Renaissance Technologies Corp

2.48%

Vanguard Group Inc

2.48%

Millennium Management LLC

2.12%

Discover more

Frequently Asked Questions

What is Curis Inc share price today?

Can Indians buy Curis Inc shares?

How can I buy Curis Inc shares from India?

Can Fractional shares of Curis Inc be purchased?

What are the documents required to start investing in Curis Inc stocks?

What are today’s High and Low prices of Curis Inc?

What are today’s traded volumes of Curis Inc?

What is today’s market capitalisation of Curis Inc?

What is the 52 Week High and Low Range of Curis Inc?

How much percentage Curis Inc is down from its 52 Week High?

How much percentage Curis Inc is up from its 52 Week low?

What are the historical returns of Curis Inc?

Who is the Chief Executive Officer (CEO) of Curis Inc?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*